AbbVie Inc. (NYSE:ABBV) remains one of the largest biopharmaceutical companies in the world, with a market capitalization around $386.47 billion and a portfolio spanning immunology, oncology, neuroscience, ophthalmology, and aesthetics. While investors once viewed AbbVie largely through the lens of Humira, the company’s growth profile has shifted dramatically as newer therapies scale.
That transition is a major reason the AbbVie stock outlook has stayed constructive even after Humira’s patent cliff pressured legacy revenue. Strong sales from immunology blockbusters Skyrizi and Rinvoq have helped offset declines, while neuroscience contributions and broader diversification supported revenue growth through 2025.
Over the past 52 weeks, AbbVie shares gained 25.8%, with the stock up 15.3% over the past six months. The stock reached a 52-week high of $244.81 in October 2025, though it has since pulled back roughly 10% from that peak—potentially creating a more interesting entry point for long-term investors who still believe in the company’s pipeline strength.
AbbVie Stock Has Outperformed the Market and Its Sector
The AbbVie stock outlook also benefits from the company’s strong relative performance. Over the same 52-week period, the S&P 500 Index ($SPX) rose 15.4%, and it gained 9.4% over the past six months. That means (NYSE:ABBV) has outpaced the broader market in both time frames.
Compared to the healthcare sector, AbbVie’s outperformance looks even more notable. The State Street Health Care Select Sector SPDR ETF (NYSEARCA:XLV) gained 5.6% over the past year and 14.4% over the past six months, trailing AbbVie’s longer-term run. This suggests AbbVie has been a leader inside its sector rather than simply riding general market momentum.
Q3 Beat Expectations as Skyrizi and Rinvoq Delivered
AbbVie’s most recent quarterly performance reinforced investor confidence. On Oct. 31, the company reported solid fiscal Q3 2025 results, beating Wall Street expectations. Skyrizi and Rinvoq once again posted robust double-digit growth, helping counterbalance the ongoing Humira decline.
Beyond the core numbers, AbbVie has continued expanding through acquisitions and partnerships. The company has moved forward with deals involving Capstan Therapeutics and Gilgamesh Pharmaceuticals, while also signing a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona. In addition, AbbVie entered an exclusive licensing agreement with RemeGen to commercialize a bispecific antibody aimed at advanced solid tumors—an example of how management is building optionality across multiple therapeutic areas.
These actions support the AbbVie stock outlook by showing that leadership is not relying solely on organic growth, but also actively investing to refresh the pipeline and broaden future revenue sources.
Q4 Earnings Expectations Are Rising
Looking ahead, AbbVie will report fourth-quarter 2025 results on Feb. 4, before the market opens. Wall Street expects earnings per share to rise 22.7% year over year to $2.65 on a diluted basis.
Analysts also see meaningful growth into the next fiscal year. EPS is projected to climb 43.9% annually to $14.32 in fiscal 2026, reflecting optimism that AbbVie’s post-Humira portfolio can deliver stronger profitability and stabilize long-term earnings power.
Another positive for the AbbVie stock outlook is consistency. The company has beaten consensus estimates in each of the last four quarters, giving investors reason to believe AbbVie can deliver another solid report—especially if Skyrizi and Rinvoq continue outperforming expectations.
Analyst Ratings and Price Targets: What Wall Street Thinks
AbbVie stock currently holds a consensus “Moderate Buy” rating from 28 analysts. That includes 15 “Strong Buy” ratings, one “Moderate Buy,” and 12 “Hold” ratings. However, the tone has become slightly less bullish over the past month, with “Strong Buy” ratings slipping from 16 to 15.
Wolfe Research recently downgraded AbbVie from “Outperform” to “Peer Perform,” arguing that the stock already reflects much of the upside from Skyrizi and Rinvoq. In other words, some analysts want greater visibility into what the next phase of growth looks like before becoming more aggressive.
Even with that caution, price targets remain supportive. AbbVie’s mean price target sits at $245.80, implying roughly 11.5% upside from current levels. The Street-high estimate of $289 suggests upside potential of about 31.1% if AbbVie continues executing and investor sentiment improves.
For investors, the takeaway is clear: the AbbVie stock outlook remains positive, but expectations are no longer low. The next earnings report may be a key catalyst in determining whether Abbvie stock can reclaim its highs and push into a new leg of long-term growth.
Featured Image: Megapixl @ Mopic
